Samsung Biologics is a fully integrated CDMO offering state-of-the-art contract development and manufacturing services. With proven regulatory approvals, the largest capacity, and the fastest throughput, Samsung Biologics is an award-winning partner of choice and is uniquely able to support the development and manufacturing of biologics products at every stage of the process while meeting the evolving needs of biopharmaceutical companies worldwide.
Unlock the market timeline & signal feed
8 signals in the last 90 days.
The order this company entered each market — oldest to newest
Korean News Portal Content
Korean News Portal Content
Sign up to see the full signal feed
How Samsung Biologics's international expansion compares to its competitors
Samsung BiologicsYouBars show relative size across the companies compared.
Columns5| Company | Markets | New markets | Momentum | Activity | Expansion score |
|---|---|---|---|---|---|
 Samsung BiologicsYou | 0 | 0 | -100% | 8 | 57 |
Not hiring right now
Sign up to track this company and get alerted the moment something changes.
The delivery of safe, high-quality medicines demands a culture where precision and compliance are deeply ingrained at every level. Dr Diane Black, EVP and Chief Quality Officer at Samsung Biologics, shares how our quality approach is put into practice through continuous process improvement. Our quality teams maintain a consistent presence on the manufacturing floor, providing real-time oversight and hands-on support throughout production. This close alignment strengthens process control, keeps p ...
EndedKOSPI closed nearly flat at 6475.63 amid Middle East tensions, while KOSDAQ surged 2.51% to 1203.84, breaking 1200 for first time since 2000.
KOSPI rose 2.25% to 8228.70 driven by semiconductor stocks, with SK Hynix surging 9.31% and Samsung Electronics up 2.68%, while KOSDAQ fell 3.36% amid polarized market conditions.
KOSPI fell 1.38% to 6598.87 on April 30 amid profit-taking after hitting record highs. Samsung Electronics dropped 2%, while foreigners sold 1.46 trillion won worth of shares.
Unlock verified emails & direct dials
Free · No credit card needed
Quick answers about Samsung Biologics's business, markets, and growth signals.
Pubrio glocalizes business, people, and intent data from 50+ local sources into one global graph, giving AI and revenue teams full‑market visibility.
© 2026 Pubrio. All rights reserved.
